TheraRadar
← Back
Data updated: Jun 28, 2026

Eli Lilly

LLY Big Pharma
MetabolicOncologyImmunology Execution: Good

Indianapolis-based pharma with leading positions in diabetes (Mounjaro, Trulicity) and Alzheimer's (Donanemab). Fast-growing obesity franchise with Zepbound.

$41.3B
Revenue (2024)
$750.0B
Market Cap
-
Trials
3
New Drugs (2yr)
Modality:
17 Small Molecules 19 Biologics

FDA Novel Drug Designations

(2016-2025)
12 Novel 2 First-in-Class 2 Orphan 3 Breakthrough 2 Accelerated 5 Priority Review 4 Fast Track
See 12 novel approvals →
2025 INLURIYO (IMLUNESTRANT TOSYLATE) Fast Track
2024 EBGLYSS (LEBRIKIZUMAB-LBKZ) Fast Track
2024 KISUNLA (DONANEMAB-AZBT) Breakthrough · Priority Review · Fast Track
2023 OMVOH (MIRIKIZUMAB-MRKZ)
2022 MOUNJARO (TIRZEPATIDE) First-in-Class
2020 RETEVMO (SELPERCATINIB) Orphan · Breakthrough · Priority Review · Accelerated
2019 REYVOW (LASMIDITAN SUCCINATE) First-in-Class
2018 EMGALITY (GALCANEZUMAB-GNLM) Priority Review
2018 OLUMIANT (BARICITINIB)
2017 VERZENIO (ABEMACICLIB) Priority Review · Fast Track
2016 TALTZ (IXEKIZUMAB)
2016 LARTRUVO (OLARATUMAB) Orphan · Breakthrough · Priority Review · Accelerated

Eli Lilly at a Glance

  • Leading 16 drug targets across portfolio
  • Fast trial execution (15 months median completion)

Upcoming FDA Decisions

Full Calendar →
Sep 11, 2026 — Pixclara (Floretyrosine F 18 or 18F-FET)
Dec 3, 2026 — Zanzalintinib (XL-092) + atezolizumab
Jan 20, 2027 — Foundayo (orforglipron)
+2 more dates (Pro)

Eli Lilly's Recent FDA Approvals

Eli Lilly secured 3 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

FOUNDAYO NDA
2026-04-01
orforglipron calcium
1 INDICATIONS AND USAGE FOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended.
INLURIYO NDA
2025-09-25
imlunestrant tosylate
Breast Cancer
EBGLYSS BLA
2024-09-13
lebrikizumab-lbkz
Atopic Dermatitis

Eli Lilly's Therapeutic Areas

Eli Lilly's approved drugs and pipeline span 5 therapeutic areas, led by Metabolic and Oncology, across 19 biologic and 17 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Metabolic 39%
16 drugs Phase 3: 128 Phase 2: 50 Phase 1: 156
Oncology 26%
7 drugs Phase 3: 40 Phase 2: 105 Phase 1: 165
Immunology 18%
3 drugs Phase 3: 68 Phase 2: 41 Phase 1: 27
Neurology 11%
3 drugs Phase 3: 36 Phase 2: 22 Phase 1: 29
Dermatology 6%
3 drugs Phase 3: 24 Phase 2: 7 Phase 1: 6

Eli Lilly's Top Competitors

Eli Lilly's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Roche, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Oncology, Immunology, Neurology, Dermatology
Roche big-pharma
Oncology, Immunology, Neurology, Metabolic
Baxter specialty
Oncology, Dermatology, Metabolic
AbbVie big-pharma
Immunology, Oncology, Neurology
Johnson & Johnson big-pharma
Oncology, Immunology, Metabolic

Eli Lilly Pipeline Snapshot

Eli Lilly has 904 active clinical programs from ClinicalTrials.gov — 296 Phase 3, 225 Phase 2 and 383 Phase 1.

296
Phase 3
225
Phase 2
383
Phase 1

Phase 3 Readout Calendar Pro

8 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q3 2026
Retatrutide
Diabetes Mellitus, Type 2
Estimated · fresh NCT06260722
Q3 2026
LY3650150
Perennial Allergic Rhinitis (PAR)
Estimated · fresh NCT06339008
Q3 2026
Baricitinib
Systemic Juvenile Idiopathic Arthritis
Estimated · fresh NCT04088396
Unlock 5 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • MOUNJARO leads revenue
  • • 5 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Metabolic pipeline focus
  • • 8 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 242/364 completed
  • • Speed: 15 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges